Novartis Ag (NVS) FCF Margin (QoQ) (2009 - 2026)
Novartis Ag (NVS) FCF Margin (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.37 Bn | 633.61 Bn | 17.26 Bn |
| 2 | AbbVie | 471.07 Bn | 464.50 Bn | 12.70 Bn |
| 3 | Merck | 378.82 Bn | 371.68 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn |
| 5 | Astrazeneca | 259.11 Bn | 254.21 Bn | 12.86 Bn |
| 6 | Amgen | 237.62 Bn | 223.63 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.34 Bn | 180.16 Bn | 6.22 Bn |
| 8 | Pfizer | 161.05 Bn | 149.36 Bn | 10.94 Bn |
| 9 | Gsk | 106.03 Bn | 101.87 Bn | 8.24 Bn |
| 10 | Sanofi | 55.24 Bn | 47.86 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6,754.00 |
| Mar 31, 2026 | -5,371.00 |
| Dec 31, 2025 | 7,222.00 |
| Sep 30, 2025 | 4,256.00 |
| Jun 30, 2025 | -15,814.00 |
| Mar 31, 2025 | 17,157.00 |
| Jun 30, 2024 | 21,978.00 |
| Mar 31, 2024 | -18,057.00 |
| Dec 31, 2023 | -23,331.00 |
| Sep 30, 2023 | 20,190.00 |
| Jun 30, 2023 | -1,862.00 |
| Mar 31, 2023 | 5,064.00 |
| Dec 31, 2022 | -9,244.00 |
| Sep 30, 2022 | 6,225.00 |
| Jun 30, 2022 | -6,861.00 |
| Mar 31, 2022 | 9,819.00 |
| Dec 31, 2021 | 109,869.00 |
| Sep 30, 2021 | -113,147.00 |
| Jun 30, 2021 | -5,295.00 |
| Mar 31, 2021 | 8,534.00 |